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Abstract
Background: Acute coronary syndromes (ACS; myocardial infarction or unstable angina) can induce posttraumatic stress
disorder (PTSD), and ACS-induced PTSD may increase patients’ risk for subsequent cardiac events and mortality. Objective:
To determine the prevalence of PTSD induced by ACS and to quantify the association between ACS-induced PTSD and
adverse clinical outcomes using systematic review and meta-analysis. Data Sources: Articles were identified by searching
Ovid MEDLINE, PsycINFO, and Scopus, and through manual search of reference lists.
Methodology/Principal Findings: Observational cohort studies that assessed PTSD with specific reference to an ACS event
at least 1 month prior. We extracted estimates of the prevalence of ACS-induced PTSD and associations with clinical
outcomes, as well as study characteristics. We identified 56 potentially relevant articles, 24 of which met our criteria
(N=2383). Meta-analysis yielded an aggregated prevalence estimate of 12% (95% confidence interval [CI], 9%–16%) for
clinically significant symptoms of ACS-induced PTSD in a random effects model. Individual study prevalence estimates
varied widely (0%–32%), with significant heterogeneity in estimates explained by the use of a screening instrument
(prevalence estimate was 16% [95% CI, 13%–20%] in 16 studies) vs a clinical diagnostic interview (prevalence estimate was
4% [95% CI, 3%–5%] in 8 studies). The aggregated point estimate for the magnitude of the relationship between ACS-
induced PTSD and clinical outcomes (ie, mortality and/or ACS recurrence) across the 3 studies that met our criteria (N=609)
suggested a doubling of risk (risk ratio, 2.00; 95% CI, 1.69–2.37) in ACS patients with clinically significant PTSD symptoms
relative to patients without PTSD symptoms.
Conclusions/Significance: This meta-analysis suggests that clinically significant PTSD symptoms induced by ACS are
moderately prevalent and are associated with increased risk for recurrent cardiac events and mortality. Further tests of the
association of ACS-induced PTSD and clinical outcomes are needed.
Citation: Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, et al. (2012) Posttraumatic Stress Disorder Prevalence and Risk of Recurrence in Acute
Coronary Syndrome Patients: A Meta-analytic Review. PLoS ONE 7(6): e38915. doi:10.1371/journal.pone.0038915
Editor: Leonardo Fontenelle, Institute of Psychiatry at the Federal University of Rio de Janeiro, Brazil
Received February 20, 2012; Accepted May 14, 2012; Published June 20, 2012
Copyright:  2012 Edmondson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants HL-088117 and CA-156709 from the National Institutes of Health, Bethesda, MD. Its contents are solely the
responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health.
Dr Edmondson is supported by NIH grant KM1CA156709. Supported in part by Columbia University’s CTSA grant No.UL1RR024156 from NCRR/NIH. No additional
external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dee2109@columbia.edu
Introduction
In recent decades, survival rates after acute coronary syndrome
[ACS; ST-segment elevation myocardial infarction (STEMI),
non–ST-segment elevation myocardial infarction (NSTEMI) or
unstable angina (UA)] have steadily increased [1,2]. Thus, for the
1.4 million ACS patients discharged annually from US hospitals,
as well as the 200,000 in Italy, 136,000 in France, and similar
numbers of patients across Europe and throughout the world,
quality of life after ACS has become vitally important. Ironically,
though the survival benefit conferred by the adoption of new
technologies, interventions, and treatment guidelines is a great
triumph of modern medicine, it may have also increased the
number of patients for whom survival means living with
posttraumatic stress disorder (PTSD) due to the ACS event.
In the Diagnostic and Statistical Manual of Mental Disorders (Fourth
Edition; DSM-IV) [3], life-threatening illness is recognized as an
event that can elicit PTSD. Posttraumatic stress disorder is an
anxiety disorder initiated by an exposure to a traumatic event,
such as combat, disaster, or sexual assault, and is characterized by
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38915symptoms such as re-experiencing (e.g., intrusive thoughts,
nightmares), cognitive or behavioral avoidance of reminders of
the event, and physiological hyperarousal. It is associated with
abnormal amygdala, prefrontal cortex, and hippocampal function
[4] as well as abnormal neuroendocrinologic characteristics [5]. At
this stage, however, the prevalence of ACS-induced PTSD is
unknown.
It is also unclear whether ACS-induced PTSD, like other
psychosocial vulnerabilities such as depression, is associated with
worse survival after ACS. However, epidemiological and obser-
vational evidence suggests that PTSD due to traumatic events
other than ACS is related to increased risk of incident
cardiovascular disease [6,7], and some previous research has
found that ACS-induced PTSD also increases patients’ subsequent
risk for recurrent cardiac events and mortality [8,9,10]. This
review was driven by two questions: What is the prevalence of
ACS-induced PTSD, and what is the prospective association
between ACS-induced PTSD and objective clinical outcomes,
specifically, recurrent cardiac events and mortality?
Methods
Search Strategy
We sought to identify all studies that reported a valid estimate of
the prevalence of ACS-induced PTSD. To be included, studies
must have been observational cohorts and must have assessed
PTSD with specific reference to an ACS event that had occurred
at least 1 month prior to the PTSD assessment. Further, studies
must have used a self-report PTSD screening instrument or
clinical interview designed or specifically altered to query about
only ACS-induced PTSD, not PTSD due to any other type of
traumatic event. Potentially relevant articles were identified by
searching the biomedical electronic databases Ovid MEDLINE,
PsycINFO and Scopus. Dates searched were 1948 to July Week 2,
2011, and the search was conducted on July 21, 2011. All relevant
subject headings and free-text terms were used to represent PTSD
and ACS and the sets of terms were combined with AND. Terms
for MEDLINE were: exp Stress Disorders, Traumatic/OR
ptsd.tw. OR (post-traumatic OR (post adj traumatic)).tw or
posttraumatic.tw. OR acute stress disorder$.tw. OR asd.tw, exp
Acute Coronary Syndrome/OR acute coronary.tw. OR acs.tw
OR exp Myocardial Infarction/OR myocardial infarct$.tw. OR
(mi or ami).tw. OR (heart adj attack$).tw. OR ((post adj mi) or
postmi).tw. OR (stemi or nstemi).tw. OR ((preinfarction or
unstable) adj angina$).tw. These terms were adapted for the other
databases. Additional records were identified by scanning the
reference lists of relevant studies and reviews and by employing the
Related Articles feature in PubMed and the Cited Reference
Search in ISI Web of Science.
Study Selection
To determine the studies to be assessed further, two authors
(S.R., L.F.) independently read the, title or abstract of every record
retrieved. All potentially relevant articles were investigated as full
text. Where differences in opinion existed, they were resolved by
consensus.
Database Construction and Coding
From studies describing the prevalence of ACS-induced PTSD,
we abstracted PTSD rates and characteristics of the study and
sample (Table 1). Only current cases of ACS-induced PTSD due to
the index ACS event were included in PTSD prevalence rates.
Where multiple publications from the same cohort were identified,
we chose the publication with the largest sample size and the
earliest post-ACS assessment of PTSD (eg, von Ka ¨nel et al [10]
was included in the PTSD and clinical outcomes analysis but was
not included in the prevalence analyses, because the study by
Guler et al [11] had a larger sample size that included the von
Ka ¨nel et al. patients and included a gold standard clinical
interview for PTSD). One study’s characteristics were uncertain
[12], and the study authors could not be contacted to obtain this
information, so this study was discarded. The coding of all articles
included demographic information (eg, sex, age, and race), sample
size, study location (eg, United States, Europe), method of PTSD
assessment (eg, clinical interview or questionnaire), and timing of
PTSD assessment. From the longitudinal outcome studies, clinical
outcomes (cardiac hospital readmission and combined cardiac
readmission and all-cause mortality) were abstracted.
Quantitative Methods
Comprehensive MetaAnalysis (version 2, BioStat Software,
Engelwood, NJ) served as the statistical platform for completing all
statistical tests and associated graphic results. To summarize the
prevalence findings, we computed prevalence point estimates using
these formulas:
Logit Event Rate = Log [Event Rate/(1 2 Event Rate)].
Event Rate Standard Error = !(1/(Event Rate ? Sample Size)/
(1/[(12Event Rate) ? Sample Size]),
We computed 95% confidence intervals (CIs) using this formula:
Lower Limit = Logit Event Rate 2 (1.96 ? Logit Event Rate
Standard Error).
Upper Limit = Logit Event Rate + (1.96 ? Logit Event Rate
Standard Error).
For meta-analytic tests of ACS-induced PTSD prevalence, in
addition to the overall random-effects model, we used sensitivity
analyses to assess evidence of moderator effects for the prevalence
results across a number of methodological factors. These factors
included the method used to assess ACS-induced PTSD, the
location of the study (United States vs other), and whether studies
explicitly included patients with NSTEMI and UA. Further, meta-
regression analysis was used to test the association between study
prevalence rates and timing of the PTSD assessment (number of
months after ACS), study publication date, and sample age and sex
composition. Heterogeneity assessments preceded all meta-analyt-
ic tests concerning PTSD prevalence and clinical outcomes. There
was statistically significant heterogeneity, so random-effects models
were used to estimate and test effects.
We calculated an aggregated point estimate for the risk ratio
associated with a positive screen for PTSD on clinical outcome
categories including cardiac hospitalization and a combined
endpoint of cardiac re-hospitalization and all-cause mortality.
Log-transformed risk ratios and 95% CIs were calculated for each
study using the reported effect size and estimates of the SE of each
effect drawn from data reported in the article. When articles
reported multiple models, we selected the model with the highest
level of covariate adjustment. For meta-analytic tests of the
association of ACS-induced PTSD and clinical outcomes, there
were too few studies to test for moderator effects. To address the
issue of publication bias, we calculated a fail-safe N.
Results
Literature Search
We initially identified 548 articles, and 2 coders agreed that 48
articles required full reading. Of these 48 potentially relevant
articles plus another 8 identified from references, 24 met our
criteria for inclusion (see Figure 1).
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Figure 2 shows the prevalence rates of clinically significant
symptoms of ACS-induced PTSD reported for each of the 24
studies (N=2383) and an aggregated estimate of approximately
12% (95% CI, 9%–16%), determined using meta-analytic tests.
Significant heterogeneity in prevalence rates existed, with reported
rates ranging from 0% to 32% (Q23=120.09; P,.001; I
2=80.85).
There was no evidence of publication bias (Figure 3).
Sources of Heterogeneity in Prevalence Estimates
Assessment method. The PTSD prevalence rates varied
significantly by type of assessment (Q1=59.85; P,.001), as shown
in Figure 4. Compared with the overall aggregate PTSD rate of
approximately 12%, the aggregate prevalence estimate in the 17
studies in which patients were assessed solely with screening
questionnaires was 16% (95% CI, 13%–20%; Q16=43.89;
P,.001; I
2=63.55), compared with 4% in the 7 studies in which
patients were assessed with clinical interviews (95% CI, 3%–5%;
Q6=3.34; P=.77; I
2=0.00).
Timing of PTSD assessment. The mean number of months
between the event and PTSD assessment across studies was 10.24;
however, 1 study [13] assessed PTSD almost 10 years after the
ACS event and found a prevalence of 31%. Excluding that study,
all other studies assessed PTSD within 2 years, with a mean of 5.7
months after ACS. Once the outlier study was excluded, the
timing of PTSD assessment was unrelated to prevalence (P=.29).
Publication date. Later publication date was related to lower
estimates of PTSD prevalence and accounted for 5% of the
variance in estimates (P=.01).
Location of study. We compared prevalence rates by
whether studies were conducted in the United States (7 studies)
[14,15,16,17,18,19,20] or elsewhere (17 studies: Canada [21],
Israel [9,22,23,24], United Kingdom
[13,25,26,27,28,29,30,31,32], and Europe [11,33,34]). Study
prevalence rates did not vary by study location (Q1=.26; P=.61).
Sample Demographics
The mean age of the participants varied from 53 to 67 years. A
younger mean age was significantly related to a greater prevalence
rate in the 21 studies in which data on age were reported
(standardized meta-regression weight =.25; P,.001). The pro-
portion of the study sample that was male varied from 56% to
100% but was unrelated to PTSD prevalence in the 21 studies in
which data on sex were reported (P=.87). There were not enough
studies with racial/ethnic diversity to conduct meta-analytic tests.
Inclusion of patients with NSTEMI and UA. Two studies
explicitly included patients with NSTEMI or UA (N=460;
Figure 1. Search strategy flowchart.
doi:10.1371/journal.pone.0038915.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38915Figure 2. ACS-induced PTSD prevalence estimates. Note: The area of each square is proportional to the study’s weight in the meta-analysis,
and each line represents the confidence interval around the estimate. The diamond represents the aggregate estimate, and its lateral points indicate
confidence intervals for this estimate.
doi:10.1371/journal.pone.0038915.g002
Figure 3. Funnel plot to assess publication bias across prevalence studies.
doi:10.1371/journal.pone.0038915.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38915prevalence =12%; 95% CI=9%–15%), and their aggregated
prevalence estimate did not differ significantly from those of
studies that did not explicitly include NSTEMI or UA patients
(P=.73).
Association with Clinical Outcomes
Table 2 provides a description of the 3 prospective studies
(N=609) that reported associations between ACS-induced PTSD
and clinical outcomes [9,10,17]. Each study used a different PTSD
assessment tool; mean patient follow-up varied from 1 to 3.5 years;
and sample sizes varied from 65 to 297. The primary clinical
outcome for 2 studies [9,10] was readmission to the hospital for
nonfatal cardiac events (i.e., recurrent MI, elective and non
elective intracoronary stenting, bypass surgery, pacemaker im-
plantation, cardiac dysrhythmia, cerebrovascular event; Shemesh
et al. included hospitalization for hypertension or its complica-
tions), and for the third [8] it was a composite of cardiac
readmission [i.e., recurrent MI, unstable angina, or urgent/
emergency coronary revascularization procedures (percutaneous
coronary intervention, coronary artery bypass grafting, or
percutaneous transluminal coronary angioplasty)] and all-cause
mortality.
Using the most conservative estimates available (Figure 5), the
risk ratio associated with a positive screen for ACS-induced PTSD
was 2.00 (95% CI, 1.69–2.37). While publication bias is difficult to
assess with 3 studies, examination of the funnel plot did not suggest
missing studies in which no relationship between PTSD symptoms
and clinical outcomes was found (Figure 6); a fail-safe N estimate
suggested that 27 such null studies would be required for the
aggregate point estimate to be nonsignificant. We conducted a
sensitivity analysis by calculating the aggregate risk ratio without
the Shemesh et al. study because it was not powered to adjust for
covariates that may have attenuated the association between ACS-
induced PTSD and clinical outcomes. The aggregate risk ratio
without the Shemesh et al. study was only slightly smaller (risk
ratio, 1.98; 95% CI, 1.68, 2.35), suggesting that the main finding
was not unduly influenced by the Shemesh et al. study.
Discussion
In recent years, cardiologists and the broader medical
community have become increasingly aware that psychological
disorders, particularly depression, are common in patients with
ACS and are associated with adverse clinical outcomes
[35,36,37,38,39]. Even so, abundant evidence suggests that
psychological disorders are underrecognized and undertreated in
cardiac populations [40,41]. While awareness of depression has
increased in cardiology practice, awareness of the possibility of
Figure 4. ACS-induced PTSD prevalence estimates by diagnostic interview or screening questionnaire. Note: The area of each square is
proportional to the study’s weight in the meta-analysis, and each line represents the confidence interval around the estimate. The diamond
represents the aggregate estimate, and its lateral points indicate confidence intervals for this estimate.
doi:10.1371/journal.pone.0038915.g004
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PTSD as primarily a disorder of combat veterans or sexual assault
survivors. Indeed, even in academic and community mental health
clinics, only a very small proportion of PTSD cases from all causes
are identified [42,43]. This under-diagnosis is likely more
pronounced in cardiology practice.
To our knowledge, this is the first meta-analytic review of ACS-
induced PTSD. We found a 12% prevalence of clinically
significant ACS-induced PTSD among ACS patients and, based
on a small number of studies, a doubling of risk of mortality and
recurrent cardiac events among ACS patients with PTSD
symptoms. In previous qualitative literature reviews, [44,45]
investigators have examined the possible risk for PTSD following
ACS. However, those reviews do not include more recent, larger,
and methodologically rigorous studies that investigated both
prevalence of ACS-induced PTSD and its association with risk
of ACS recurrence and mortality. Given that 1.4 million patients
are discharged from US hospitals each year with a diagnosis of
ACS [46], these results suggest that 168 000 ACS patients in the
United States alone will develop clinically significant PTSD
symptoms due to ACS. Among ACS patients in the United States,
20% are hospitalized again within 1 year of the ACS event [47],
and 60% of the $1.5 billion spent annually to treat ACS in the
United States is due to subsequent hospitalizations [47]. It appears
that ACS-induced PTSD may contribute to repeated hospitaliza-
tion and mortality at a rate very similar to that reported for
depression (approximate doubling of risk [48]).
Prevalence of ACS-Induced PTSD
Although the overall prevalence of ACS-induced PTSD was
12%, individual study prevalence estimates ranged from 0% to
32%, suggesting a considerable degree of heterogeneity. As
expected, prevalence estimates based on screening questionnaires
were greater than estimates based on clinical interviews. Also,
similar to within-study findings that younger age is associated with
greater likelihood of ACS-induced PTSD, younger mean sample
age was related to greater prevalence estimates across studies.
Finally, later publication date was associated with lower prevalence
rates, though the association was modest, which may reflect
reduced psychological trauma due to advances in treatment or the
fact that the definition of ACS has broadened in recent years to
include less severe disease. However, since we found that the
inclusion of patients with less severe ACS (ie, NSTEMI and UA)
was unrelated to prevalence estimates, advances in treatment may
well be responsible for slightly better post-ACS psychological
outcomes in recent years. Timing of PTSD assessment, study
location, and sex of the sample were unrelated to prevalence
estimates.
Symptoms and Clinical Outcomes of ACS-Induced PTSD
Our analyses indicated that ACS-induced PTSD symptoms are
associated with an approximate doubling of risk for recurrent
cardiac events or mortality. Two of the 3 studies included in the
analysis [10,17] adjusted for multiple demographic and clinical
covariates, suggesting that the association is not likely to be
confounded by demographic characteristics and disease severity.
Important caveats to this review include the fact that only
studies with relatively small sample sizes have addressed ACS-
induced PTSD, many of which were marginally powered to detect
associations with outcomes over relatively short intervals. Further-
more, no study to date has been sufficiently powered to test for
potential mechanisms or effect modifiers of the relationship
between ACS-induced PTSD and adverse clinical outcomes.
Thus, although this meta-analysis was able to quantify more
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38915precisely the magnitude of the increased risk of clinical events due
to ACS-induced PTSD symptoms, a clear need for additional
research remains.
Caveats aside, there is now considerable evidence for a link
between PTSD due to various life stressors and subsequent heart
disease [49], but the mechanisms for this association are not yet
known [50]. If the apparent association between ACS-induced
PTSD and ACS recurrence and mortality holds up to further
scrutiny, many of the candidate mechanisms that require years to
develop and be associated with an increase in risk, and so more
proximate or trigger mechanisms should be explored, as the
follow-up between PTSD and a recurrence/mortality is fairly
short in this review (ie, follow-up periods for the 3 included studies
ranged from 1–3 years). We know that both ACS and PTSD are
associated with sympathetic activation and elevated proinflamma-
tory cytokines, including C-reactive protein [51], tumor necrosis
factor, and interleukin 1 [51]. It is likely that the additive effects of
the inflammation found in patients with PTSD may adversely
affect the heart [52]. Pharmacologic and psychotherapy treat-
ments for PTSD due to noncardiac events reduce PTSD
symptoms [53] and might reduce accompanying inflammation,
potentially producing more favorable clinical outcomes in ACS
patients. It seems likely, but has not yet been tested, that reducing
symptoms of PTSD could improve adherence to post-ACS
treatment regimens [9,54].
Study Limitations
The present review has several limitations. First, since we did
not include unpublished articles or articles from non–peer-
reviewed journals, we are more likely to have excluded negative
findings [55]. Second, although some articles included in this
review [17,56] were from samples large enough to report useful
data on within-sex, race, or ethnicity estimates, or rates by ACS
type, our findings were based on cruder estimates, such as the
proportion of each sample that was male, which may limit our
conclusions about the relationship of demographic factors to
prevalence. Finally, none of the studies included in this review
reported on the severity of the ACS event in terms of the types of
critical care that may have become necessary after the ACS, such
as intensive care unit (ICU) admission or major surgery. While
there seemed to be no difference in PTSD rates by ACS type
(STEMI vs NSTEMI/UA), a growing literature suggests that
exposure to critical care for other types of medical events can
induce PTSD in up to 64% of ICU patients [57].
Figure 5. Association of ACS-induced PTSD with adverse clinical outcome. Note: The size of the box associated with each study’s estimate
represents the precision of the estimate, and the line represents the confidence interval around the estimate.
doi:10.1371/journal.pone.0038915.g005
Figure 6. Funnel plot to assess publication bias across outcome studies.
doi:10.1371/journal.pone.0038915.g006
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We were able to locate only one PTSD treatment study in ACS
patients: a phase I safety trial of cognitive behavioral therapy for
ACS-induced PTSD [58]. The study was not powered to detect
differences between the treatment and control groups (the intent-
to-treat analysis included 51 participants), but small-to-moderate
reductions in PTSD symptoms were reported, and no adverse
clinical outcomes or safety concerns were associated with
treatment. Thus, more research is needed to determine whether
treatment can reduce ACS-induced PTSD symptoms and reduce
the associated risk for ACS recurrence and mortality.
While little research exists on treatment of ACS-induced PTSD,
a growing body of literature suggests risk factors for PTSD
diagnosis and symptom severity after ACS. These risk factors
include intense fear [28], perceived life threat, lack of control [59],
helplessness and chest pain [60] during the ACS, dissociation
during the event, acute stress disorder [41], depression symptoms
during hospitalization [21], and history of psychiatric disorder
before ACS [21], alexithymia [26], or neuroticism [33]. Demo-
graphic factors associated with ACS-induced PTSD in some
studies include younger age [61], female sex [21], ethnic minority
status, and low socioeconomic status [61]. While these scattered
risk factor studies have been useful, a unified risk stratification
strategy is warranted for predicting which patients are most likely
to develop ACS-induced PTSD.
In conclusion, across published studies concerning the preva-
lence of ACS-induced PTSD and its associations with clinical
outcomes, a few general conclusions can be drawn: (1) ACS is a
traumatic event for many, and ACS-induced PTSD is relatively
common, with approximately 12% experiencing clinically signif-
icant PTSD symptoms and 4% meeting full diagnostic criteria for
the disorder, and (2) based on a small number of studies, clinically
significant symptoms of ACS-induced PTSD appear to double
patients’ risk of recurrent cardiac events and mortality. These
results identify areas requiring further research; in particular,
studies testing treatments for ACS-induced PTSD are needed.
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